Enhanced solubility and bioavailability of apigenin via preparation of solid dispersions of mesoporous silica nanoparticles

Iranian Journal of Pharmaceutical Research

Volumn 18, Issue 1, 2019, Pages 168-182

  Huang, Yannian ^a   Zhao, Xiuhua ^a   Zu, Yuangang ^a   Wang, Lu ^a   Deng, Yiping ^a   Wu, Mingfang ^a   Wang, Huimei ^a  

^a NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

Apigenin; Bioavailability; Dissolution; Mesoporous silica nanoparticles; Solid dispersion; Solubility

Indexed keywords

APIGENIN; DEIONIZED WATER; DRUG CARRIER; MESOPOROUS SILICA NANOPARTICLE; NANOCRYSTAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BRUNAUER, EMMETT AND TELLER SURFACE AREA ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; FOURIER TRANSFORM INFRARED SPECTROSCOPY; GAS CHROMATOGRAPHY; GRAVIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL PARAMETERS; SCANNING ELECTRON MICROSCOPY; SOLID DISPERSION; SURFACE AREA; TEMPERATURE; THERMOGRAVIMETRY; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

EID: 85061367420     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Skerget M, Kotnik P, Hadolin M, Hras HR, Simonic M and Knez Z. Phenols, proanthocyanidins, flavones and flavonols in some plant materials and their antioxidant activities. Food Chem. (2005) 89: 191-8.
2. Tong X, Van Dross RT, Abu-Yousif A, Morrison AR and Pelling JC. Apigenin prevents UVB-induced cyclooxygenase 2 expression: coupled mRNA stabilization and translational inhibition. Mol. Cell. Biol. (2007) 27: 283-96.
3. Patel D, Shukla S and Gupta S. Apigenin and cancer chemoprevention: Progress, potential and promise (Review). Int. J. Oncol. (2007) 30: 233-45.
4. Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, Wu J, Xu X, Qin J and Xie L. Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell Int. (2013) 13: 54.
5. Zhu Y, Wu J, Li S, Wang X, Liang Z, Xu X, Hu Z, Lin Y, Chen H, Qin J, Mao Q and Xie L. Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. Mol. Med. Rep. (2015) 11: 1004-8.
6. Patil RH, Babu RL, Naveen Kumar M, Kiran Kumar KM, Hegde SM, Nagesh R, Ramesh GT and Sharma SC. Anti-Inflammatory effect of apigenin on LPS-Induced pro-inflammatory mediators and AP-1 factors in human lung epithelial cells. Inflammation (2016) 39: 138-47.
7. Fang J, Xia C, Cao ZX, Zheng JZ, Reed E and Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. (2005) 19: 342-53.
8. Gopalakrishnan A, Xu CJ, Nair SS, Chen C, Hebbar V and Kong AN. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. Arch. Pharm. Res. (2006) 29: 633-44.
9. Hessenauer A, Montenarh M and Gotz C. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int. J. Oncol. (2003) 22: 1263-70.
10. Lee WJ, Chen WK, Wang CJ, Lin WL and Tseng TH. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol. Appl. Pharm. (2008) 226: 178-91.
11. Zhang J, Liu D, Huang Y, Gao Y and Qian S. Biopharmaceutics classification and intestinal absorption study of apigenin. Int. J. Pharm. (2012) 436: 311-7.
12. Xiao M, Shao YD, Yan WD and Zhang ZZ. Measurement and correlation of solubilities of apigenin and apigenin 7-O-rhamnosylglucoside in seven solvents at different temperatures. J. Chem. Thermodyn. (2011) 43: 240-3.
13. Xiao M, Yan WD and Zhang ZZ. Solubilities of apigenin in ethanol plus water at different temperatures. J. Chem. Eng. Data (2010) 55: 3346-8.
14. Banerjee K, Banerjee S, Das S and Mandal M. Probing the potential of apigenin liposomes in enhancing bacterial membrane perturbation and integrity loss. J. Colloid Interface Sci. (2015) 453: 48-59.
15. Ding BY, Chen H, Wang C, Zhai YJ and Zhai GX. Preparation and in-vitro evaluation of apigenin loaded lipid nanocapsules. J. Nanosci. Nanotechnol. (2013) 13: 6546-52.
16. Zhao LL, Zhang L, Meng L, Wang J and Zhai GX. Design and evaluation of a self-microemulsifying drug delivery system for apigenin. Drug Dev. Ind. Pharm. (2013) 39: 662-9.
17. Zhai YJ, Guo SS, Liu CH, Yang CF, Dou JF, Li LB and Zhai GX. Preparation and in-vitro evaluation of apigenin-loaded polymeric micelles. Colloid Surf. A (2013) 429: 24-30.
18. Ding SM, Zhang ZH, Song J, Cheng XD, Jiang J and Jia XB. Enhanced bioavailability of apigenin via preparation of a carbon nanopowder solid dispersion. Int. J. Nanomedicine (2014) 9: 2327-33.
19. Al Shaal L, Shegokar R and Muller RH. Production and characterization of antioxidant apigenin nanocrystals as a novel UV skin protective formulation. Int. J. Pharm. (2011) 420: 133-40.
20. Zhang JJ, Huang YT, Liu DP, Gao Y and Qian S. Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement. Eur. J. Pharm. Sci. (2013) 48: 740-7.
21. Vo CL, Park C and Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur. J. Pharm. Biopharm. (2013) 85: 799-813.
22. Kim MS, Kim JS, Park HJ, Cho WK, Cha KH and Hwang SJ. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int. J. Nanomedicine (2011) 6: 2997-3009.
23. Kim SA, Kim SW, Choi HK and Han HK. Enhanced systemic exposure of saquinavir via the concomitant use of curcumin-loaded solid dispersion in rats. Eur. J. Pharm. Sci. (2013) 49: 800-4.
24. Hoffmann F, Cornelius M, Morell J and Froba M. Silica-based mesoporous organic-inorganic hybrid materials. Angew. Chem. Int. Edit. (2006) 45: 3216-51.
25. Anglin EJ, Cheng LY, Freeman WR and Sailor MJ. Porous silicon in drug delivery devices and materials. Adv. Drug Deliv. Rev. (2008) 60: 1266-77.
26. Jiao J, Li X, Zhang S, Liu J, Di DH, Zhang Y, Zhao QF and Wang SL. Redox and pH dual-responsive PEG and chitosan-conjugated hollow mesoporous silica for controlled drug release. Mat. Sci. Eng. C-Mater. (2016) 67: 26-33.
27. Feng Y, Panwar N, Tng DJH, Tjin SC, Wang K and Yong KT. The application of mesoporous silica nanoparticle family in cancer theranostics. Coord. Chem. Rev. (2016) 319: 86-109.
28. Wu L, Zhang HJ, Wu MH, Zhong YF, Liu XW and Jiao Z. Dual-templating synthesis of multi-shelled mesoporous silica nanoparticles as catalyst and drug carrier. Micropor. Mesopor. Mat. (2016) 228: 318-28.
29. Bouchoucha M, Cote MF, C-Gaudreault R, Fortin MA and Kleitz F. Size-controlled functionalized mesoporous silica nanoparticles for tunable drug release and enhanced anti-tumoral activity. Chem. Mater. (2016) 28: 4243-58.
30. Paris JL, de la Torre P, Manzano M, Cabanas MV, Flores AI and Vallet-Regi M. Decidua-derived mesenchymal stem cells as carriers of mesoporous silica nanoparticles. In-vitro and in-vivo evaluation on mammary tumors. Acta Biomater. (2016) 33: 275-82.
31. Ge K, Ren HH, Sun WT, Zhao Q, Jia G, Zang AM, Zhang CM and Zhang JC. Walnut kernel-like mesoporous silica nanoparticles as effective drug carrier for cancer therapy in-vitro. J. Nanopart. Res. (2016) 18: 11.
32. Xu XB, Lu SY, Gao CM, Feng C, Wu C, Bai X, Gao NN, Wang ZY and Liu MZ. Self-fluorescent and stimuli-responsive mesoporous silica nanoparticles using a double-role curcumin gatekeeper for drug delivery. Chem. Eng. J. (2016) 300: 185-92.
33. Mehrasa M, Asadollahi MA, Nasri-Nasrabadi B, Ghaedi K, Salehi H, Dolatshahi-Pirouz A and Arpanaei A. Incorporation of mesoporous silica nanoparticles into random electrospun PLGA and PLGA/gelatin nanofibrous scaffolds enhances mechanical and cell proliferation properties. Mat. Sci. Eng. C-Mater. (2016) 66: 25-32.
34. Sun DQ, Hussain HI, Yi ZF, Rookes JE, Kong LX and Cahill DM. Mesoporous silica nanoparticles enhance seedling growth and photosynthesis in wheat and lupin. Chemosphere (2016) 152: 81-91.
35. McCarthy CA, Ahern RJ, Dontireddy R, Ryan KB and Crean AM. Mesoporous silica formulation strategies for drug dissolution enhancement: A review. Expert Opin. Drug Deliv. (2016) 13: 93-108.
36. Shi NQ, Lei YS, Song LM, Yao J, Zhang XB and Wang XL. Impact of amorphous and semicrystalline polymers on the dissolution and crystallization inhibition of pioglitazone solid dispersions. Powder Technol. (2013) 247: 211-21.
37. Kusakabe K, Ichiki K, Hayashi JI, Maeda H and Morooka S. Preparation and characterization of silica—polyimide composite membranes coated on porous tubes for CO2 separation. J. Membrane Sci. (1996) 115: 65-75.
38. Kioul A and Mascia L. Compatibility of polyimide-silicate ceramers induced by alkoxysilane silane coupling agents. J. Non-Cryst. Solids (1994) 175: 169-86.